Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
11 hedge funds and large institutions have $870K invested in Biostar Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
378% more capital invested
Capital invested by funds: $182K → $870K (+$688K)
120% more funds holding
Funds holding: 5 → 11 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$191K |
| 2 |
SIM
Spark Investment Management
New York
|
+$64.4K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$34.3K |
| 4 |
N
Natixis
Paris,
France
|
+$18.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $663K | +$191K | +17,682 | +63% |
|
|
SIM
2
Spark Investment Management
New York
| $85K | +$64.4K | +5,957 | New |
|
|
VKH
3
Virtu KCG Holdings
New York
| $46K | +$34.3K | +3,177 | New |
|
4
California Public Employees Retirement System
Sacramento,
California
| $28K | – | – | – |
|
|
N
5
Natixis
Paris,
France
| $24K | +$18.5K | +1,714 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $12K | +$9.22K | +853 | New |
|
|
U
7
UBS
Zurich,
Switzerland
| $7K | +$195 | +18 | +4% |
|
8
Citigroup
New York
| $3K | +$1.98K | +183 | New |
|
9
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$20K | -3,885 | Closed |
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$86 | +8 | New |
|
12
Morgan Stanley
New York
| – | +$259 | +24 | New |
|
BSPM Hedge Fund Activity: Q4 2013 in Review
11 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q4 2013, worth a combined $870K — up 378% from $182K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BSPM positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $191K. The largest seller was Citadel Advisors, exiting entirely with an estimated $20K sold.
- 11 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q4 2013, up from 5 in Q3 2013.
- Funds reported $870K of Biostar Pharmaceuticals, Inc. stock for Q4 2013, up 378% quarter-over-quarter.
- 7 funds opened new Biostar Pharmaceuticals, Inc. positions in Q4 2013 and 1 closed out, a net change of +6 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q4 2013 was Renaissance Technologies, an estimated $191K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q4 2013 was Citadel Advisors, an estimated $20K sold.
Based on aggregated 13F filings for Q4 2013.